Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm associated with the human T-cell leukemia virus type-I (HTLV-1); prognosis still remains very poor. We retrospectively reviewed the treatment of 198 patients with acute-, lymphoma- and unfavorable chronic-type ATL (aggressive ATL) diagnosed from 2005 to 2014 in a hospital located in an area of Japan in which HTLV-1 is highly endemic. One-hundred forty-three, and 35 patients were treated using OPEC/MPEC and VCAP-AMP-VECP, respectively. OPEC/MPEC was mainly used until around 2010, and gradually switched to VCAP-AMP-VECP, especially for younger patients. The 2-year overall survival for patients treated by VCAP-AMP-VECP was significantly higher than that using OPEC/MPEC for patients < 70 years old (y.o.), but not for patients ≥ 70 y.o. A less intensive chemotherapy OPEC/MPEC could be performed without reducing dose intensity, even in elderly patients, and its therapeutic outcome is not inferior to that of VCAP-AMP-VECP. It is difficult to draw definite conclusion from this small retrospective study; however, OPEC/MPEC may represent an alternative option for elderly patients with aggressive ATL.

中文翻译：

---

侵袭性成人T细胞白血病/淋巴瘤的治疗：在HTLV-1高流行地区的一家医院进行的回顾性研究。

成人T细胞白血病/淋巴瘤（ATL）是与人I型T细胞白血病病毒（HTLV-1）相关的外周T细胞肿瘤；预后仍然很差。我们回顾性分析了2005年至2014年在日本HTLV-1高度流行地区的一家医院诊断为急性，淋巴瘤和不利的慢性ATL（攻击性ATL）的198例患者的治疗情况。分别使用OPEC / MPEC和VCAP-AMP-VECP治疗了143例和35例患者。OPEC / MPEC主要用于直到2010年左右，并逐渐切换到VCAP-AMP-VECP，特别是对于年轻患者。VCAP-AMP-VECP治疗的2年总生存率显着高于使用OPEC / MPEC的70岁以下患者（年岁），但不超过70岁以上的患者 即使在老年患者中，也可以在不降低剂量强度的情况下进行强度较小的OPEC / MPEC化疗，其治疗效果不逊于VCAP-AMP-VECP。这项小型回顾性研究很难得出明确的结论。然而，对于有侵略性ATL的老年患者，OPEC / MPEC可能是另一种选择。